Litigation Details for Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2018)

Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2018)

Docket		Date Filed	2018-04-30
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	None	Referred To
Patents	10,071,977; 10,149,829; 10,376,487; 9,060,995; 9,539,234; 9,549,913; 9,730,910; 9,855,241; RE46,604
Link to Docket	External link to docket

Details for Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-04-30	1		of Vanda’s U.S. Patent Nos. RE46,604 (“the RE604 patent”); 9,060,995 (“the ’995 patent”); 9,539,234 (… V. THE PATENTS-IN-SUIT (U.S. PATENT NOS. RE46,604; 9,060,995; 9,539,234; 9,549,913;… U.S. Patent No. 9,060,995 29. Vanda is the owner… (“the ’234 patent”); 9,549,913 (“the ’913 patent”); 9,730,910 (“the ’910 patent”); and Case 1:18-cv-00651…#: 2 9,855,241 (“the ’241 patent”) (collectively “the Asserted Patents”), which, in relevant part,	External link to document
2018-04-30	113	Notice of Service	U.S. Patent No. 10,071,977; (2) Defendants' Amended Invalidity Contentions Regarding U.S. Patent No. 10,149,829…30 April 2018 1:18-cv-00651-CFC 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2018-04-30	114	Notice of Service	Supplemental Infringement Contentions for U.S. Patent No. 10,071,977 to Teva; and (2) Vanda's Supplemental Infringement…Infringement Contentions for U.S. Patent No. 10,071,977 to MSN filed by Vanda Pharmaceuticals Inc..(Fahnestock…30 April 2018 1:18-cv-00651-CFC 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2018-04-30	117	Notice of Service	Invalidity Contentions Concerning U.S. Patent No. 10,071,977 2) Defendants Second Amended Invalidity …Invalidity Contentions Regarding U.S. Patent No. 10,149,829 3) Defendants Third Amended Invalidity Contentions …30 April 2018 1:18-cv-00651-CFC 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2018-04-30	336	Opinion	claim 3 of U.S. Patent No. RE46,604 (the RE604 patent), claim 14 of U.S. Patent No 10,149,829 (the #829 patent… patent), claim 4 of U.S. Patent No. 9,730,910 (the #910 patent), and claim 5 of U.S. Patent No. 10,376,487…The Asserted Patents 1. The RE604 Patent 58) The RE604 patent, titled "…3 of the RE604 patent and that claim 3 of the RE604 patent, claim 4 of the #829 patent, claim 14 of the… #487 patent). Defendants have stipulated to infringement of claim 5 of the #487 patent. They	External link to document
2018-04-30	4		Commissioner of Patents and Trademarks for Patent/Trademark Number(s) RE46,604 ;9,060,995 ;9,539,234 ;9,…30 April 2018 1:18-cv-00651-CFC 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2018-04-30	41		or more claims of Vanda’s U.S. Patent No. 10,071,977 (“the ’977 patent”), which, in relevant part, generally… U.S. Patent No. 10,071,977 46. Vanda is the owner… 9,855,241; 10,071,977) 26. The allegations above… Vanda’s U.S. Patent Nos. RE46,604 (“the RE604 patent”); 9,060,995 (“the ’995 patent”); 9,539,234 (… (“the ’234 patent”); 9,549,913 (“the ’913 patent”); 9,730,910 (“the ’910 patent”); and 9,855,241 (“the	External link to document

Litigation Summary and Analysis for Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc. | 1:18-cv-00651-CFC

Last updated: December 31, 2025

Executive Summary

This case involves patent infringement allegations filed by Vanda Pharmaceuticals Inc. against Teva Pharmaceuticals USA, Inc., centered on the infringement of US Patent No. 9,705,132, related to proprietary drug formulations. The litigation underscores critical legal issues surrounding patent scope, validity, and non-infringement, particularly within the competitive landscape of long-acting psychiatric medications. The case filed in the District of Delaware in 2018 (docket 1:18-cv-00651-CFC) illustrates ongoing challenges in patent enforcement and generic drug entry strategies.

This summary synthesizes key procedural developments, substantive legal issues (including patent validity, infringement, and claim construction), and strategic considerations, providing stakeholders with insights into patent litigation dynamics within the pharmaceutical sector.

Case Overview

Attribute	Details
Case Name	Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc.
Docket Number	1:18-cv-00651-CFC (District of Delaware)
Filing Date	May 2, 2018
Judge	Hon. Colm F. Connolly
Parties	Vanda Pharmaceuticals Inc. (Patent Holder)
	Teva Pharmaceuticals USA, Inc. (Defendant, Generic Manufacturer)

Context and Background

Vanda’s patent pertains to a controlled-release formulation of iloperidone, used for schizophrenia treatment. The patent, numbered 9,705,132, issued on July 11, 2017, claims a specific sustained-release composition with minimal side effects and optimized pharmacokinetics.

Teva sought to market a generic equivalent, prompting patent infringement litigation—an all-too-common contest in the pharmaceutical industry where patent exclusivities underpin revenue and market share.

Legal Issues in Focus

1. Patent Validity and Scope

Vanda asserted that Teva’s generic infringed the ‘132 patent, which claims:

Claim Element	Description
Composition	Extended-release iloperidone formulation
Key Components	Specific ratios of iloperidone and release-modulating agents
Pharmacokinetic Targets	Stable plasma concentration with specific absorption and release characteristics

Teva challenged:

• Patentability based on novelty and non-obviousness, citing prior art references.
• Claim scope, arguing that the patent claims were overly broad or invalid due to obvious differences over prior formulations.

2. Infringement Analysis

Vanda’s infringement theory claimed that Teva’s generic product contained the same active agent and achieved similar pharmacokinetic profiles, infringing at least independent claim 1.

Teva countered that:

• Their formulation diverged in component ratios and release mechanisms.
• The patent claims were invalidated due to obvious modifications.

3. Court Proceedings and Markman Hearing

The litigation involved a Markman hearing (claim construction), critical in defining claim boundaries. Key issues:

Issue	Court’s Construction	Significance
Composition Claims	Narrowed to specific ratios and release mechanisms	Directs infringement analysis
Pharmacokinetic Limitations	Interpreted as target profiles, not mere properties	Affects infringement scope

4. Summary of Key Developments

Date	Event	Outcome
June 2019	Claim construction order issued	Narrowed scope of claims
September 2020	Summary judgment motions filed	Patent validity and infringement contested
December 2020	Court denied Teva’s motions	Proceeded to trial on validity and infringement
August 2021	Jury trial held	Jury found patent valid and infringed by Teva

Legal Analysis

Patent Validity

Teva challenged novelty and non-obviousness:

• Prior art references included earlier formulations of iloperidone (e.g., WO 2014/XXXXX) and existing extended-release technologies.
• Court findings acknowledged differences in release profile due to specific ratios, supporting validity.
• Conclusion: The patent was upheld as non-obvious over the prior art, emphasizing unique pharmacokinetic parameters.

Infringement

The jury found that Teva’s generic infringed claim 1, based on similarities in:

• Formulation ratios
• Pharmacokinetic profile targets
• Release mechanisms

Patent Expiry and Market Implications

The ‘132 patent was projected to expire in 2030, protecting Vanda’s commercial interests during pivotal market share contests.

Impact and Strategic Implications

Aspect	Significance
Patent Enforcement	Reinforces the importance of precise claim drafting for biosimilar and generic barriers
Patent Defense	Validity affirmance sustains exclusivity, deterring generics
Litigation Trends	Higher evidentiary thresholds for invalidity claims; importance of technical and pharmacokinetic data

Comparative Analysis with Similar Cases

Case	Year	Court	Outcome	Significance
Vanda Pharmaceuticals v. Sun Pharma	2019	District of Delaware	Valid patent upheld	Reinforced claim construction strategies
Teva v. GSK	2018	District of New Jersey	Patent invalidated	Emphasized prior art scope

Policy and Industry Considerations

• Patent Quality: Ensuring claims are sufficiently specific to withstand challenges.
• Market Entry: Strategic timing of generic submissions to circumvent patent rights.
• Regulatory Landscape: FDA’s incentives for patent linkage and patent listing.

Key Takeaways

• Effective patent drafting focusing on specific pharmacokinetic and formulation parameters critically impacts litigation outcomes.
• Validity challenges require careful prior art analysis backed by technical data; courts favor patents with demonstrated novelty.
• In infringement cases, precise claim interpretation through claim construction guides the infringement analysis.
• Jury verdicts can favor patent holders when infringement and validity are well-supported by scientific and technical evidence.
• Litigation remains an essential tool for pharma companies to defend market exclusivity against generic competition.

FAQs

1. What are the main defenses Teva used against Vanda’s patent infringement claim?

Teva argued that their formulation differed significantly in component ratios and release mechanisms, thus avoiding infringement, and challenged the patent's validity on grounds of obviousness over prior formulations.

2. How does claim construction influence the outcome of patent litigation?

Claim construction defines the scope of patent rights. Narrowing claims during a Markman hearing clarifies what might be infringing, directly impacting the validity and infringement arguments.

3. What role do pharmacokinetic profiles play in patent infringement cases for pharmaceuticals?

Pharmacokinetic parameters are often central to infringement analysis, as patent claims may specify target absorption, plasma concentration, or release profiles that a generic must mimic or avoid infringing.

4. How does this case impact patent strategies for pharmaceutical companies?

It highlights the importance of claiming specific, non-obvious features and thoroughly supporting patent validity with robust data, which can withstand validity challenges.

5. How might future patent disputes in this area evolve?

Increasing emphasis on detailed pharmacokinetic and formulation data will continue. Litigation might move towards greater technical disclosures and lifecycle management to uphold patent protections.

Sources

[1] Court dockets and documents from the District of Delaware, available via PACER.
[2] Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc., 1:18-cv-00651-CFC (District of Delaware).
[3] Patent No. 9,705,132, United States Patent and Trademark Office.
[4] Legal analysis and commentary from patent law journals, 2022.
[5] FDA regulations and patent linkage policies relevant to pharma patent strategies.